Redesigning nature's poisons to create anti-tumor reagents.
Immunotoxins are conjugates of cell-reactive antibodies and toxins or their subunits. In this report, the chemistry, biology, pharmacokinetics, and anti-tumor effects of first generation immunotoxins; the preparation of improved second generation immunotoxins that display greater anti-tumor efficacy; and the role of genetic engineering in creating third-generation immunotoxins are discussed.
Vitetta
E S
ES
Department of Microbiology, University of Texas Southwestern Medical Center, Dallas 75235.
Fulton
R J
RJ
May
R D
RD
Till
M
M
Uhr
J W
JW
D000818:Animals; D000970:Antineoplastic Agents; D002986:Clinical Trials as Topic; D006801:Humans; D000922:Immunotoxins / Q000493:pharmacokinetics / Q000633:toxicity; D009374:Neoplasms, Experimental / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000922:Immunotoxins; D011994:Recombinant Proteins